Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

被引:55
作者
Bernstein, DI
Schleiss, MR
Berencsi, K
Gonczol, E
Dickey, M
Khoury, P
Cadoz, M
Meric, C
Zahradnik, J
Duliege, AM
Plotkin, S
机构
[1] Childrens Hosp, Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA
[2] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
[3] Aventis Pasteur, Swiftwater, PA USA
[4] Albert Szent Gyorgyi Med Univ, H-6701 Szeged, Hungary
[5] Aventis Pasteur, Marcy Letoile, France
[6] Chiron Corp, Emeryville, CA 94608 USA
关键词
D O I
10.1086/339003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Development of a vaccine for prevention of congenital cytomegalovirus (CMV) disease is a priority. This study evaluated a "prime-boost" strategy by comparing the safety and immunogenicity of 3 doses of subunit CMV glycoprotein B (gB) vaccine plus MF59 (a squalene-in-water emulsion), 2 doses of a canarypox recombinant vaccine expressing CMVgB (ALVAC-CMVgB) followed by 2 doses of the subunit gB vaccine, 3 doses of both vaccines administered concomitantly, and placebo in 105 healthy, CMV-seronegative adults. Systemic adverse events were rare, but local reactions were common in all groups. After the first subunit vaccination, neutralizing antibody titers in the prime-boost group were comparable to those in subjects receiving 2 subunit vaccinations, indicating a priming effect of ALVAC-CMVgB. However, after the final dose, antibody and cell-mediated immune responses were not significantly different among the groups. All 3 vaccine regimens induced high-titer antibody and lymphoproliferative responses, but no benefit for priming or simultaneous vaccination was detected.
引用
收藏
页码:686 / 690
页数:5
相关论文
共 14 条
[1]   A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne) [J].
Adler, SP ;
Plotkin, SA ;
Gonczol, E ;
Cadoz, M ;
Meric, C ;
Ben Wang, JA ;
Dellamonica, P ;
Best, AM ;
Zahradnik, J ;
Pincus, S ;
Berencsi, K ;
Cox, WI ;
Gyulai, Z .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :843-846
[2]   A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects [J].
Berencsi, K ;
Gyulai, Z ;
Gönczöl, E ;
Pincus, S ;
Cox, WI ;
Michelson, S ;
Kari, L ;
Meric, C ;
Cadoz, M ;
Zahradnik, J ;
Starr, S ;
Plotkin, S .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (08) :1171-1179
[3]   INDUCTION OF COMPLEMENT-DEPENDENT AND COMPLEMENT-INDEPENDENT NEUTRALIZING ANTIBODIES BY RECOMBINANT-DERIVED HUMAN CYTOMEGALO-VIRUS GP55-116 (GB) [J].
BRITT, WJ ;
VUGLER, L ;
STEPHENS, EB .
JOURNAL OF VIROLOGY, 1988, 62 (09) :3309-3318
[4]   IMMUNIZATION WITH CANARYPOX VIRUS EXPRESSING RABIES GLYCOPROTEIN [J].
CADOZ, M ;
STRADY, A ;
MEIGNIER, B ;
TAYLOR, J ;
TARTAGLIA, J ;
PAOLETTI, E ;
PLOTKIN, S .
LANCET, 1992, 339 (8807) :1429-1432
[5]  
Demmler G J, 1996, Adv Pediatr Infect Dis, V11, P135
[6]   Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine [J].
Frey, SE ;
Harrison, C ;
Pass, RF ;
Yang, E ;
Boken, D ;
Sekulovich, RE ;
Percell, S ;
Izu, AE ;
Hirabayashi, S ;
Burke, RL ;
Duliège, AM .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (05) :1700-1703
[7]   PRECLINICAL EVALUATION OF AN ALVAC (CANARYPOX)-HUMAN CYTOMEGALOVIGRUS GLYCOPROTEIN-B VACCINE CANDIDATE [J].
GONCZOL, E ;
BERENCSI, K ;
PINCUS, S ;
ENDRESZ, V ;
MERIC, C ;
PAOLETTI, E ;
PLOTKIN, SA .
VACCINE, 1995, 13 (12) :1080-1085
[8]   A RAPID MICRONEUTRALIZATION ASSAY FOR CYTOMEGALOVIRUS [J].
GONCZOL, E ;
FURLINI, G ;
IANACONE, J ;
PLOTKIN, SA .
JOURNAL OF VIROLOGICAL METHODS, 1986, 14 (01) :37-41
[9]   CURRENT MANAGEMENT OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH AIDS [J].
JACOBSON, MA .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (08) :917-923
[10]   A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant [J].
Pass, RF ;
Duliegè, AM ;
Boppana, S ;
Sekulovich, R ;
Percell, S ;
Britt, W ;
Burke, RL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (04) :970-975